Acquisition of Cialis (Tadalafil) rights in Hong Kong, Macau, and South Korea.
This acquisition signifies Zuellig Pharma's strategic expansion into the men's health market in key Asian territories. By securing rights to a well-established brand like Cialis, the company aims to leverage its existing distribution networks and market expertise to drive growth and cater to an unmet medical need, potentially increasing revenue and market share in these regions.
The acquisition focuses on Hong Kong, Macau, and South Korea, representing significant markets within East Asia. This move allows Zuellig Pharma to strengthen its presence in the region's pharmaceutical landscape, particularly in the growing men's health segment, and capitalize on local market dynamics.
The acquisition covers Hong Kong, Macau, and South Korea.
This expands Zuellig Pharma's men's health product portfolio in Asia.
Zuellig Pharma acquired Cialis (Tadalafil) rights from Eli Lilly.
The acquisition covers Hong Kong, Macau, and South Korea.
This expands Zuellig Pharma's men's health product portfolio in Asia.
Zuellig Pharma 已从礼来公司手中收购了领先的男性健康产品 Cialis (他达拉非) 在香港、澳门和韩国的所有权利。此次战略收购扩展了 Zuellig Pharma 在这些关键亚洲市场的男性健康领域的产品组合，旨在增强其市场地位和产品供应。
登录后可保存信号笔记。
登录